Proclaim
Device Neuromodulation
PDI 05415067020215
General payments
$2,098,473
Research payments
$259,630
Through program year 2025, $2,098,473 in general payments and $259,630 in research payments were reported against Proclaim (Neuromodulation).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $54,614 | 3 |
| 2024 | General | $445,317 | 5,749 |
| 2023 | General | $652,055 | 6,228 |
| 2023 | Research | $30,961 | 10 |
| 2022 | General | $1,001,102 | 6,779 |
| 2022 | Research | $174,054 | 155 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 109 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 52 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
18,756 general · 168 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.